JP2024537321A5 - - Google Patents
Info
- Publication number
- JP2024537321A5 JP2024537321A5 JP2024522067A JP2024522067A JP2024537321A5 JP 2024537321 A5 JP2024537321 A5 JP 2024537321A5 JP 2024522067 A JP2024522067 A JP 2024522067A JP 2024522067 A JP2024522067 A JP 2024522067A JP 2024537321 A5 JP2024537321 A5 JP 2024537321A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- cancer
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/123371 | 2021-10-12 | ||
| CN2021123371 | 2021-10-12 | ||
| PCT/CN2022/124968 WO2023061419A1 (en) | 2021-10-12 | 2022-10-12 | Anti-cd3 antibodies with cross-reactivity to human and cynomolgus proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024537321A JP2024537321A (ja) | 2024-10-10 |
| JP2024537321A5 true JP2024537321A5 (enExample) | 2025-10-22 |
Family
ID=85987307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024522067A Pending JP2024537321A (ja) | 2021-10-12 | 2022-10-12 | ヒトおよびカニクイザルタンパク質に対して交差反応性を有する抗ｃｄ３抗体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250011427A1 (enExample) |
| EP (1) | EP4416182A4 (enExample) |
| JP (1) | JP2024537321A (enExample) |
| CN (1) | CN118510803A (enExample) |
| WO (1) | WO2023061419A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN122070305A (zh) * | 2023-09-21 | 2026-05-19 | 艾科联生物科技(上海)有限公司 | 多特异性抗体及其用途 |
| EP4791782A1 (en) * | 2023-10-11 | 2026-08-19 | Abany Biosciences (Hefei) Co. Ltd. | An anti-cd3 activable antibody and the use thereof |
| WO2025103425A1 (en) * | 2023-11-15 | 2025-05-22 | Concept To Medicine Biotech Co., Ltd. | Multispecific antibodies and uses thereof |
| CN122213233A (zh) * | 2026-05-13 | 2026-06-16 | 赛业（苏州）生物科技有限公司 | 一种cd3抗体及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ598732A (en) * | 2009-10-27 | 2014-09-26 | Amgen Res Munich Gmbh | Dosage regimen for administering a cd19xcd3 bispecific antibody |
| AR103488A1 (es) * | 2015-01-23 | 2017-05-10 | Sanofi Sa | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 |
| HK1251480A1 (zh) * | 2015-09-21 | 2019-02-01 | Aptevo Research And Development Llc | Cd3结合多肽 |
| CN118126180A (zh) * | 2016-12-22 | 2024-06-04 | 第一三共株式会社 | 抗cd3抗体和包含所述抗体的分子 |
| US11319371B2 (en) * | 2017-06-05 | 2022-05-03 | Numab Therapeutics AG | Anti-CD3 antibodies |
| TW202010757A (zh) * | 2018-04-11 | 2020-03-16 | 美商英伊布里克斯公司 | 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途 |
-
2022
- 2022-10-12 EP EP22880355.7A patent/EP4416182A4/en active Pending
- 2022-10-12 WO PCT/CN2022/124968 patent/WO2023061419A1/en not_active Ceased
- 2022-10-12 CN CN202280082275.7A patent/CN118510803A/zh active Pending
- 2022-10-12 US US18/700,235 patent/US20250011427A1/en active Pending
- 2022-10-12 JP JP2024522067A patent/JP2024537321A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019536430A5 (enExample) | ||
| JP2023509448A5 (enExample) | ||
| JP2020511152A5 (enExample) | ||
| JP2022512132A5 (enExample) | ||
| JP2021525546A5 (enExample) | ||
| JP2023543031A5 (enExample) | ||
| Zhu et al. | Multifunctional receptor-targeting antibodies for cancer therapy | |
| JP2020525032A5 (enExample) | ||
| RU2014103784A (ru) | Антитело, блокирующее agr2, и его применение | |
| RU2012112340A (ru) | Гуманизированные моноклональные антитела к сеа с созревшей аффинностью | |
| JP2023540526A5 (enExample) | ||
| JP2016526904A5 (enExample) | ||
| JP2018502050A5 (enExample) | ||
| Golay et al. | Design and validation of a novel generic platform for the production of tetravalent IgG1-like bispecific antibodies | |
| JP2012523848A5 (enExample) | ||
| JP2018505681A5 (enExample) | ||
| JP2024016024A5 (enExample) | ||
| JP2024541680A5 (enExample) | ||
| JP2023529842A5 (enExample) | ||
| JP2025069432A5 (enExample) | ||
| JP2017521054A5 (enExample) | ||
| JP2020522280A5 (enExample) | ||
| JP2023536461A5 (enExample) | ||
| JP2020522281A5 (enExample) | ||
| JP2020533965A5 (enExample) |